XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating Activities    
Net income (loss) $ 260 $ (14,536)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Stock-based compensation expense 210 515
Depreciation and amortization 3 113
Change in fair value of long-term receivables (20)  
Change in fair value of derivative liabilities 20  
Bad debt expense   200
Net gain on disposal of assets (4,736)  
Changes in operating assets and liabilities:    
Accounts and other receivables   1,054
Prepaid and other current assets 625 1,485
Accounts payable (178) (1,713)
Accrued compensation and other accrued liabilities (2,411) 1,036
Operating lease liability and right-of-use asset 11 26
Deferred revenue   (230)
Net cash flows used in operating activities (6,216) (12,050)
Investing Activities    
Proceeds from maturities of short-term investments   2,504
Proceeds from the sale of legacy rare bleeding disorder program to GCBP 1,000  
Payment of transaction costs in connection with the sale of legacy rare bleeding disorder program to GCBP (589)  
Net cash flows provided by investing activities 411 2,504
Financing Activities    
Payment of dividends (7,764)  
Issuance of common stock from stock grants 2 16
Net cash flows (used in) provided by financing activities (7,762) 16
Net decrease in cash and cash equivalents (13,567) (9,530)
Cash and cash equivalents at beginning of the period 21,666 44,347
Cash and cash equivalents at end of the period 8,099 $ 34,817
Supplemental Disclosure on Non-Cash Investing and Financing Activities:    
CVR derivative liability 4,530  
Accrued transaction costs related to GCBP asset sale $ 205